ID   HUH7-R
AC   CVCL_B7TI
DR   cancercelllines; CVCL_B7TI
DR   Wikidata; Q112929797
RX   DOI=10.5282/edoc.26548;
RX   PubMed=32652772;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar).
CC   Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0336 ! Huh-7
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 6
//
RX   DOI=10.5282/edoc.26548;
RA   Messner M.;
RT   "Sorafenib resistance of hepatocellular carcinoma: antibiotics second-
RT   line to sorafenib therapy inhibit mitochondrial biogenesis and prevent
RT   tumor growth resumption.";
RL   Thesis PhD (2020), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=32652772; DOI=10.1096/fj.202001128R;
RA   Messner M., Schmitt S., Ardelt M.A., Frohlich T., Muller M., Pein H.,
RA   Huber-Cantonati P., Ortler C., Koenig L.M., Zobel L., Koeberle A.,
RA   Arnold G.J., Rothenfusser S., Kiemer A.K., Gerbes A.L., Zischka H.,
RA   Vollmar A.M., Pachmayr J.;
RT   "Metabolic implication of tigecycline as an efficacious second-line
RT   treatment for sorafenib-resistant hepatocellular carcinoma.";
RL   FASEB J. 34:11860-11882(2020).
//